Effectiveness of Bupropion in Treating Marijuana Dependent Individuals

Completed · Phase 2

Conditions studied: Marijuana Abuse, Substance-Related Disorders

In brief

A definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. Bupropion (Zyban) is a medication currently used to treat withdrawal symptoms associated with tobacco use. The purpose of this study is to determine if bupropion will help individuals stop using marijuana.

Key facts

Study ID

NCT00142870

Run by

National Institute on Drug Abuse (NIDA)

People needed

30

Starts

2005-03-01

Expected to finish

2006-05-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Current marijuana use and dependence
• Marijuana use of at least 5 times in the past 7 days or more than 25 times per month for the 3 years prior to enrollment
• Unsuccessful in a previous attempt to quit marijuana

You may not qualify if…

• Axis I disorder
• Any drug abuse or dependence other than marijuana
• Currently taking antipsychotic or antidepressant medication
• Heavy alcohol drinker (more than 20 drinks per week)
• Current nicotine dependence
• History of a seizure disorder
• Current or prior eating disorder (e.g., bulimia or anorexia nervosa)
• Heavy caffeine use (more than 300 mg per day)
• Life threatening or unstable medical illness
• Pregnant

Where it is running

• McLean Hospital, Dept. of Psychiatry — Belmont, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.